Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Fulgent Genetics's shares outstanding for the quarter that ended in Mar. 2026 was 28.9 Mil.
Fulgent Genetics's quarterly shares outstanding
declined
from Dec. 2025 (31.1 Mil) to Mar. 2026 (28.9 Mil).
It means Fulgent Geneticsbought back shares from Dec. 2025 to Mar. 2026 .
Fulgent Genetics's annual shares outstanding
increased
from Dec. 2024 (30.8 Mil) to Dec. 2025 (31.1 Mil).
It means Fulgent Geneticsissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Fulgent Genetics Shares Outstanding (EOP) Related Terms
Fulgent Genetics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FLGT vs MYGN, CSTL, BDSX: Shares Outstanding (EOP) Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 28.9 Mil mean?
Fulgent Genetics (FLGT) has a Shares Outstanding (EOP) of 28.9 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Fulgent Genetics and its competitors.
Is Fulgent Genetics' Shares Outstanding (EOP) too high?
Fulgent Genetics' current Shares Outstanding (EOP) is 28.9 Mil. Overall, Fulgent Genetics has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Shares Outstanding (EOP) compare to MYGN and CSTL?
Fulgent Genetics' Shares Outstanding (EOP) of 28.9 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Shares Outstanding (EOP) is 28.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.99, compared to a current price of $20.56 — trading 14.3% below its estimated fair value. The current Shares Outstanding (EOP) is 28.9 Mil. Fulgent Genetics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Shares Outstanding (EOP) is 28.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $20.56 is trading 14.3% below its estimated GF Value™ of $23.99.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Shares Outstanding (EOP): 28.9 Mil
GF Value™: $23.99 vs. price of $20.56 (14.3% below fair value)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
59GF Score
Get the complete analysis for FLGT
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
